Precorten

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Precorten

What is Precorten?

Precorten-V is an injectable medication used in veterinary medicine as a replacement therapy for hormones that are naturally produced by the adrenal glands. It is specifically utilized in the management of primary adrenocortical insufficiency, a condition commonly referred to as Addison's disease.

Mechanism of Action

The active ingredient in Precorten is desoxycorticosterone pivalate (DOCP). This substance belongs to a class of drugs known as mineralocorticoids. In a healthy animal, the adrenal glands produce mineralocorticoids to help the body maintain a proper balance of electrolytes—specifically sodium and potassium—and water.

When the adrenal cortex fails to produce these hormones, the body loses its ability to regulate these essential elements, which can lead to severe metabolic imbalances. Precorten acts as a long-acting substitute for these missing hormones, assisting the kidneys in retaining sodium and excreting excess potassium to maintain physiological stability.

Clinical Application

Precorten is primarily prescribed for dogs diagnosed with primary hypoadrenocorticism. Because the medication is a pure mineralocorticoid, it focuses strictly on electrolyte and water balance. It does not contain glucocorticoid activity, which is another type of hormone typically affected in Addison's disease. Consequently, it is often used in conjunction with other treatments to provide a comprehensive hormone replacement profile tailored to the animal's specific needs.

Regulatory References

  1. Prednisolone Ophthalmic: MedlinePlus Drug Information
  2. FDA Prednisolone Acetate Ophthalmic Labeling

What side effects are possible with Precorten?

Possible Side Effects and Safety Information for Precorten

Precorten (desoxycorticosterone pivalate) is a mineralocorticoid agent, and its safety profile is primarily linked to its effects on sodium and potassium balance, and fluid volume. As with other adrenocortical hormones, the risk of severe side effects increases with high or prolonged dosage.

Adverse Reactions and Systemic Effects

The most frequently reported adverse reactions in clinical use include gastrointestinal and constitutional signs such as depression/lethargy, vomiting, anorexia, polydipsia (excessive thirst), and polyuria (excessive urination). Other documented effects involve the skin and coat, weakness, diarrhea, and local reactions like pain or abscess at the injection site. Serious, though less frequent, adverse events reported post-approval include anaphylaxis (severe allergic reaction) and anemia.

Prolonged or excessive use may lead to signs of mineralocorticoid excess, including increased blood volume, edema (fluid retention), and potentially cardiac enlargement or elevated blood pressure.

Safety Restrictions and Contraindications

Precorten is contraindicated and must not be used in patients with pre-existing conditions that could be exacerbated by fluid retention and sodium effects, specifically:

  • Congestive heart disease
  • Severe renal disease
  • Edema (generalized swelling)

It is also not for use in pregnant animals, as safety has not been established. Patients should be rehydrated with saline before initiating therapy if they present with severe volume depletion or shock. Due to the risk of severe side effects from excess, patients must be closely monitored for signs of hypernatremia (high sodium) or hypokalemia (low potassium), which require dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Precorten (Prednisolone Acetate Ophthalmic Suspension) indicates that acute overdosage is unlikely to occur via the intended topical ophthalmic route of administration. Regulatory documents state that overdosage, when used as prescribed, will not ordinarily cause acute problems.


Official Overdose Actions

The primary scenario addressed in official labeling is the accidental oral ingestion of the suspension. In this event, immediate action is required as directed by regulatory authorities.

Overdose Context Official Action Mandated by Regulators
Accidental Oral Ingestion Drink fluids to dilute the product immediately
Emergency Status Seek emergency medical attention or contact a Poison Help line

Manifestations and Treatment

No specific acute ocular or systemic manifestations resulting from topical overdosage are documented in the official regulatory labels. Consequently, no specific antidote is mentioned in these overdose sections. Management of accidental ingestion focuses on the mandated supportive measure of dilution. There are no specific population-based (e.g., pediatric, geriatric) acute overdosage considerations detailed in the labeling beyond the general guidance for accidental ingestion.

Therapeutic Uses of Precorten

What Precorten Treats: Main Uses and Benefits

Precorten (Prednisolone Acetate Ophthalmic Suspension) is applied in clinical contexts where a potent anti-inflammatory agent is considered appropriate to control pronounced inflammatory processes in the eye's anterior structures. It is commonly used to help with symptomatic relief and supportive care across several therapeutic domains. The medication is used to relieve the signs of inflammation caused by various conditions, trauma, and procedures.

This treatment is relevant for addressing steroid-responsive ocular conditions, including inflammation of the cornea, conjunctiva, and internal structures like the iris and ciliary body (known as anterior uveitis). It is applicable in conditions marked by periods of heightened inflammatory responses, providing support that helps ease the overall symptom load during acute or recurrent episodes.

Precorten is applied in addressing groups of symptoms that interfere with daily functioning, focusing on pronounced eye redness (hyperemia), swelling (edema), persistent burning, soreness, and itching. By easing these disruptive symptoms, the medication contributes to improved comfort during periods of heightened symptoms.

It is also commonly used in specific clinical settings, such as to address the acute inflammatory processes occurring after eye surgery (e.g., cataract extraction) or following external damage from sources like chemical burns.


Quick Fact: Management of Inflammatory Discomfort Symptom Targeted Context of Use Therapeutic Benefit
Redness, Swelling, Burning Acute ocular inflammation, post-trauma Supports easing the overall symptom load
Anterior Uveitis, Keratitis Steroid-responsive conditions Supports general stability
Postoperative Inflammation Surgical recovery phases Assists with improving comfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is contraindicated:

  • Individuals with known or suspected hypersensitivity to Prednisolone Acetate or any component.
  • Patients with most viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis), fungal diseases, and mycobacterial infection of the eye.

Age-related eligibility rules:

  • Adults and Geriatrics: Use is established, with no overall differences in safety or effectiveness reported between these groups.
  • Pediatrics: Regulatory status varies; for some formulations, safety and effectiveness have not been established, and use may be restricted.

Eligibility-related restrictions (Conditional Use):

  • Glaucoma: Use requires routine monitoring of intraocular pressure (IOP) if treatment is 10 days or longer.
  • History of Ocular Herpes Simplex: Use requires great caution and frequent monitoring.
  • Pregnancy: Use is permitted only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Regulators recommend a decision to discontinue nursing or discontinue the drug.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility through a core set of absolute contraindications based on infectious status, particularly viral and fungal infections. For other populations, eligibility is defined by conditional use, requiring stringent patient monitoring and risk assessment, especially concerning IOP elevation and reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Precorten (Prednisolone Acetate Ophthalmic Suspension) is applied topically to the eye, resulting in minimal systemic absorption; consequently, the documented drug interaction profile in regulatory sources is highly restricted.

Interaction Scope

The most significant and consistently documented concern involves agents that interfere with the primary metabolic pathway for corticosteroids. This constitutes a pharmacokinetic interaction that can lead to Systemic Exposure Modification Risk.

Category Officially Documented Interacting Substances
Medicinal Product Categories Strong inhibitors of the Cytochrome P450 enzyme CYP3A
Specific Interacting Medicines Cobicistat-containing products
Interaction Mechanism Potential inhibition of prednisolone clearance

Official Interaction Statements and Restrictions

Co-treatment with strong CYP3A inhibitors, including cobicistat-containing products, is expected by regulatory authorities to increase the risk of systemic corticosteroid side-effects.

Regulatory documents classify this combination as one that should be avoided unless the benefit of co-use clearly outweighs the increased potential for systemic risk, in which case the patient must be monitored. No mandatory timing-based separation rules or specific population-dependent interaction cautions are officially documented for this ophthalmic suspension.

Mechanism of Action

The action of Precorten, based on its active ingredient Prednisolone, is defined by its ability to modulate core regulatory pathways at the cellular level, leading to broad anti-inflammatory and immunosuppressive actions.


Genomic Control of Inflammatory Signaling

This mechanism centers on the drug's role as an agonist for the Glucocorticoid Receptor ( GR), a molecular switch found inside the cell. Once activated, the Prednisolone-GR complex enters the nucleus to directly turn off (transrepress) genes responsible for creating numerous pro-inflammatory mediators, such as those governed by Nuclear Factor kappa B ( NF-kappa B). This modulation initiates a sustained change in cellular chemistry that results in the dampening of inflammatory physiological signaling.


Interference with Key Inflammatory Enzymes

A key consequence of the genomic action is the induced synthesis of proteins that inhibit the enzyme Phospholipase A2 ( PLA2). Since PLA2 is required to generate the precursors for inflammatory messengers (eicosanoids, like prostaglandins and leukotrienes), this molecular interference significantly limits the total quantity of signaling molecules produced at the site of action. The result is a reduced chemical signal, which contributes to a lower level of pathway activation.


Modulation of Immune Cell Traffic

The drug's mechanism also includes the suppression of molecules required for white blood cells (leukocytes) to move from the bloodstream into the tissue. By limiting the expression of adhesion molecules and chemical signals (cytokines), the drug restricts the physical infiltration of immune cells. This targeted pathway interference limits the progression of the physiological reaction and establishes the functional immunosuppressive action.

Dosage and Administration Information

How to Use Precorten: Official Administration Guidelines

Precorten (prednisolone acetate ophthalmic suspension) is strictly a topical medication for the eye. Standard clinical guidelines outline precise procedures for preparation, dosing, frequency, and discontinuation. The medicine is not to be used for injection or oral consumption.


Administration Protocol

Entity Standard Instruction
Route of Administration Topical ophthalmic instillation into the conjunctival sac.
Preparation Requirement The suspension must be shaken well immediately before each use.
Standard Adult Dose Instill one to two drops per dose.
Standard Frequency Two to four times daily (every 6 to 12 hours).
Acute Frequency Dosing frequency may be increased to one drop every hour during the initial 24 to 48 hours.
Contact Lenses Soft contact lenses should be removed before application and reinserted 15 minutes afterward.

Official Use Patterns and Constraints

The usage protocol emphasizes a specific sequence and time course. To reduce the potential for systemic absorption, the patient may be instructed to compress the tear duct (punctal occlusion) for approximately one minute following the instillation of each drop.

For chronic conditions, treatment withdrawal is managed by gradually decreasing the frequency of applications to avoid premature discontinuation. There are no specific dosage adjustments recommended for older adults. The safety and effectiveness of this product in the pediatric population have not been established, and therefore, no posology can be recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Biological Effect

Studies have explored the drug’s intended biological effect on pain and inflammation. Research is underway to further detail the drug's activity concerning inflammatory pathways.


Key Efficacy Findings

Clinical trials investigated participant outcomes related to symptom severity over a defined study period. The initial randomized controlled trials (RCTs) evaluated changes in metrics related to patient-reported status, including quality of life and daily function scores.

  • Symptom Scoring: Studies collected data on changes in standardized symptom scores. Findings were mixed in the early Phase 2 trials, while later, larger studies reported a smaller overall change in symptom severity compared to placebo.
  • Biomarker Analysis: Researchers explored the drug's association with changes in measured inflammatory biomarkers in participants' blood samples.

Evaluation of Adverse Events and Tolerability

Initial studies examined participant data related to adverse events, noting the observed frequency and type of side effects following drug administration. Studies reported common observed adverse events that included headache, mild gastrointestinal upset, and temporary injection site reactions.

  • Long-Term Monitoring: Continuing research is tracking a small cohort of participants over several years to observe the types of long-term adverse events that occur.

Future Research Directions

Research continues to investigate the drug’s potential role for individuals who have not responded adequately to prior therapies. Further investigation is underway to better understand the drug’s pharmacokinetics and whether participant response differs between various patient subsets.

Frequently Asked Questions (FAQ)

Common questions about Precorten (FAQ)


Q: How long after starting treatment do people usually feel the effects of Precorten?

Official prescribing information indicates that a patient’s condition should be re-evaluated by a healthcare professional if signs and symptoms fail to improve after two days. This reference point helps guide healthcare providers in assessing patient status.


Q: If I miss a dose of Precorten, what is the generally accepted advice?

According to patient information leaflets, if a dose has been missed, official instructions describe applying it as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory documents advise against using double or extra doses to make up for a missed application.


Q: Are the side effects from Precorten typically permanent or do they go away?

The duration of side effects can vary. Effects like temporary burning upon instillation are generally described as transient in nature. However, regulatory documents warn that certain serious adverse reactions, such as elevation of intraocular pressure (IOP) and damage to the optic nerve, are associated with prolonged use and may become irreversible.


Q: Are there any foods or drinks that should be limited while using Precorten?

Since Precorten is a topical ophthalmic suspension (eye drop), official regulatory information indicates there are no specific restrictions regarding the consumption of food or drink while using this medicine.


Q: Can Precorten affect the results of blood tests?

Precorten is applied topically to the eye, resulting in minimal absorption into the rest of the body. The drug is not known to alter standard blood test results, due to minimal systemic absorption. However, if used alongside certain medicines that inhibit the CYP3A enzyme, the risk of systemic corticosteroid side-effects that could affect lab parameters may increase.


Q: What is the generally described timeframe for a course of Precorten treatment?

The official labeling indicates that Precorten is not intended for long-term use. If the medicine is used for 10 days or longer, regulatory authorities require the routine monitoring of intraocular pressure (IOP) to manage the increased risk of complications like glaucoma.


Q: Can Precorten cause weight gain?

Systemic corticosteroids (the drug class to which Precorten belongs) can be associated with side effects such as weight gain and a round face. The minimal systemic absorption of the ophthalmic form reduces this risk, but it is acknowledged as a side effect associated with the corticosteroid class.


Q: Why do some people report feeling restless or anxious on Precorten?

Systemic use of corticosteroids is known to be associated with behavioral and mood disturbances, including anxiety. The minimal systemic absorption of the ophthalmic form reduces this risk, but it is acknowledged as a side effect associated with the corticosteroid class.


Q: Does taking Precorten impact your ability to drive?

Official patient information advises caution regarding activities like driving. Since vision may become temporarily blurred or unstable immediately after application, patients are advised in official leaflets to wait until their vision fully clears before operating a vehicle or machinery.


Q: Can Precorten affect sleep patterns?

Insomnia, or difficulty sleeping, is a known side effect associated with systemic corticosteroids, the classification of this medicine. Although the topical eye drop form has minimal absorption, the potential for this effect is linked to the core drug class.


Q: Does Precorten need to be taken with food or on an empty stomach?

Because Precorten is a sterile ophthalmic suspension intended only for topical use in the eye, there are no instructions or limitations in the regulatory documents about taking it in relation to food or on an empty stomach.


Q: What should be done if a severe or unusual side effect occurs?

Official patient safety information strongly advises that if signs of a severe allergic reaction, such as anaphylaxis, or other serious, unusual symptoms occur, official patient safety information directs users to immediately contact a healthcare professional or seek emergency medical attention.


Q: Are there specific warnings for diabetics considering Precorten?

Systemic corticosteroids can cause elevated blood sugar, a condition known as hyperglycemia. The drug class risk indicates that blood sugar monitoring may be warranted for patients with diabetes, even though systemic absorption of the topical form is minimal.


Q: Does Precorten interact with any medications for high blood pressure?

Although specific drug-to-drug interactions with high blood pressure medications are not commonly listed for the topical eye drop, systemic corticosteroids are known to potentially cause elevated blood pressure. This general risk is noted due to the drug’s classification.


Q: What happens if I accidentally take too much Precorten?

Overdosage is generally considered unlikely with the topical eye drops. If too many drops are accidentally applied to the eye, the official guidance is to wash the eye with clean water. If the medicine is accidentally swallowed, official guidance recommends contacting a physician or emergency center.


Q: Is it true that Precorten can impact bone density with long-term use?

Long-term, high-dose use of systemic corticosteroids (the drug class) is clearly linked to an increased risk of osteoporosis, which is the thinning of the bones. Although the ophthalmic form has minimal systemic absorption, this risk is inherent to the corticosteroid class of medicine.


Q: If I have an upcoming surgery, do I need to stop Precorten?

Official warnings note that the use of steroids after certain surgical procedures, such as cataract surgery, may delay healing. Official patient information states that a consultation with a healthcare professional is necessary regarding the continued use of Precorten if eye surgery is planned.


Q: Can I take Precorten if I have a pre-existing stomach ulcer?

The corticosteroid drug class is associated with an increased risk of gastrointestinal issues, including peptic ulcer and perforation, when taken systemically. While this is less likely with the topical form, this class-related risk requires assessment by a healthcare professional.


Q: Does Precorten affect fertility in men or women?

Regulatory documents explicitly state that no specific studies have been conducted in animals or humans to evaluate the potential for impairment of fertility related to the use of this drug.


Q: Can Precorten be taken at the same time as other daily medications?

If you are using any other kind of topical eye medication, such as drops or ointments, patient instructions typically recommend that you wait at least 5 to 10 minutes between applying Precorten and the other product. This allows each medicine to be absorbed properly.

How should Precorten be stored and disposed of?

The official labeling for Precorten (Prednisolone Acetate Ophthalmic Suspension) specifies strict storage and disposal requirements to ensure product quality.

Storage and Handling

The medicine must be stored at controlled room temperature, generally below 30 C (86 F), and must not be frozen. Because it is a suspension, the bottle must be shaken well before use and kept tightly closed to maintain sterility and prevent contamination. To prevent accidental ingestion, the medication must be kept out of the reach of children.

Storage Restriction Requirement
Temperature Controlled Room Temperature
Prohibited Do Not Freeze; Avoid Dropper Contact
In-Use Stability Discard after specified in-use period (e.g., 28 days)

Disposal

Expired or unused Precorten must be disposed of according to local pharmaceutical waste regulations. Healthcare professionals or pharmacists should be consulted for proper disposal methods, such as drug take-back programs, rather than discarding the product in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Precorten found in:

A-Z Index: